CICLOPIROX

Manufacturer
Encube Ethicals, Inc. | Encube Ethicals Private Limited
Effective date
2026-01-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 21:58:32

Label at a glance#

ProductCICLOPIROX
Active ingredientCICLOPIROX
Label structure15 sections

Indications and uses

Ciclopirox shampoo, 1 % is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.

Dosage and administration

Ciclopirox shampoo is not for ophthalmic, oral, or intravaginal use. Wet hair and apply approximately 1 teaspoon (5 mL) of ciclopirox shampoo to the scalp. Up to 2 teaspoons (10 ml) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes. Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between application...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ciclopirox shampoo, 1 % is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Ciclopirox shampoo is not for ophthalmic, oral, or intravaginal use.

Wet hair and apply approximately 1 teaspoon (5 mL) of ciclopirox shampoo to the scalp. Up to 2 teaspoons (10 ml) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes. Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications.

If a patient with seborrheic dermatitis shows no clinical improvement after 4 weeks of treatment with ciclopirox shampoo, the diagnosis should be reviewed.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Ciclopirox is a shampoo containing 1 % ciclopirox.

Each gram (equivalent to 0.96 mL) of ciclopirox shampoo contains 10 mg ciclopirox in a colorless and translucent shampoo base.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Local Effects

WARNINGS SECTION

If a reaction suggesting sensitivity or irritation occurs with the use of ciclopirox shampoo, treatment should be discontinued and appropriate therapy instituted.

Contact of cicloplrox shampoo with the eyes should be avoided. If contact occurs, rinse thoroughly with water.

In patients with lighter hair color, hair discoloration has been reported.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 CLINICAL TRIALS EXPERIENCE

CLINICAL TRIALS EXPERIENCE SECTION

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In 626 subjects treated with ciclopirox shampoo twice weekly in the two pivotal clinical trials, the most frequent adverse events were increased itching in 1% of subjects, and application site reactions, such as burning, erythema, and itching, also in 1 % of subjects.

6.2 POSTMARKETING EXPERIENCE

POSTMARKETING EXPERIENCE SECTION

The following adverse reactions have been identified during post approval use of ciclopirox shampoo: hair discoloration and abnormal hair texture, alopecia, irritation and rash. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 PREGNANCY

PREGNANCY SECTION

Teratogenic Effects: Pregnancy Category B

There are no adequate or well-controlled studies in pregnant women. Therefore, ciclopirox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively).

Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively).

8.3 NURSING MOTHERS

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ciclopirox shampoo is administered to a nursing woman.

8.4 PEDIATRIC USE

PEDIATRIC USE SECTION

No clinical trials have been conducted in subjects younger than 16 years.

8.5 GERIATRIC USE

GERIATRIC USE SECTION

In clinical trials, the safety and tolerability of ciclopirox shampoo in the population 65 years and older was comparable to that of younger subjects. Results of the efficacy analysis in those subjects 65 years and older showed effectiveness in 25 of 85 (29%) subjects treated with ciclopirox shampoo, and in 15 of 61 (25%) subjects treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.

11 DESCRIPTION

DESCRIPTION SECTION

Ciclopirox shampoo 1 % contains the synthetic antifungal agent, ciclopirox for topical use. Each gram (equivalent to 0.96 ml) of ciclopirox shampoo contains 10 mg ciclopirox m a shampoo base consisting of disodium laureth sulfosuccinate, laureth-2, purified water, sodium chloride, and sodium laureth sulfate.

Ciclopirox shampoo is a colorless, translucent solution. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, with the empirical formula C12H17NO2 and a molecular weight of 207.27. The GAS Registry Number is [29342-05-0]. The chemical structure is:

structurestructure

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 MECHANISM OF ACTION

MECHANISM OF ACTION SECTION

Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe3+ or Al3+), resulting in the Inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.

12.2 PHARMACODYNAMICS

PHARMACODYNAMICS SECTION

The pharmacodynamics of clcloplrox shampoo are unknown.

12.3 PHARMACOKINETICS

PHARMACOKINETICS SECTION

In a study in patients with seborrheic dermatitis of the scalp, application of 5 mL ciclopirox shampoo, 1 % twice weekly for 4 weeks, with an exposure time of 3 minutes per application, resulted in detectable serum concentrations of ciclopirox in 6 out of 18 patients. The serum concentrations measured throughout the dosing interval on Days 1 and 29 ranged from 10.3 ng/mL to 13.2 ng/ml. Total urinary excretion of ciclopirox was less than 0.5% of the administered dose.

12.4 MICROBIOLOGY

MICROBIOLOGY SECTION

Ciclopirox is fungicidalin vitro against Malassezia furfur (Pityrosporum spp.), P. ovale, and P. orbiculare.

The clinical significance of antifungal activity in the treatment of seborrheic dermatitis is not known.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

A 104-week dermal carcinogenicity study in mice was conducted with ciclopirox cream applied at doses up to 1.93% (100 mg/kg/day or 300 mglm2/day). No increase in drug related neoplasms was noted when compared to control.

The following In vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames Salmonella and E. coli assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe3+, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An in vitro cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an in vivo Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5,000 mg/kg body weight.

A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.3 times the maximum recommended human dose based on body surface area comparisons).

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

In two randomized, double-blind clinical trials, subjects 16 years and older with seborrheic dermatitis of the scalp applied ciclopirox shampoo or its vehicle twice weekly for 4 weeks. Subjects who were immune- compromised, those with psoriasis or atopic dermatitis, women of childbearing potential not using adequate contraception, and pregnant or lactating women were excluded from the clinical trials. An evaluation of the overall status of the seborrheic dermatitis, the presence and severity of erythema or inflammation, and scaling, was made at Week 4, using a scale of 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = pronounced, and 5 = severe. Effective treatment was defined as achieving a score of o (or a score of 1 If the baseline score was ≥ 3) simultaneously for status of the seborrheic dermatitis, erythema or inflammation, and scaling at Week 4.

Ciclopirox shampoo was shown to be statistically significantly more effective than vehicle in both trials. Efficacy results for the two trials are presented in Table 1 below.

Table 1. Effective Treatment Rates at Week 4 in Trials 1 and 2

Clcloplrox ShampooVehicle

Study 1

220/380 (58%)

60/192 (31%)

Study 2

65/250 (26%)

32/249 (1 3%)

Efficacy for African American subjects was not demonstrated, although only 53African American subjects were enrolled in the two pivotal trials.             

16 HOW SUPPLIED

HOW SUPPLIED SECTION

Ciclopirox shampoo, 1 % is colorless and translucent, and supplied in 120 mL plastic bottles (NOC 21922-105-52).

Discard unused product after initial treatment duration. Store between 15°C and 30°C (59° F and 86° F).

Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

The patient should be instructed to:

  • Use cicloplrox shampoo as directed by the physician. Avoid contact with the eyes. If contact occurs, rinse thoroughly with water. Ciclopirox shampoo is for external use on the scalp only. Do not swallow.
  • Use ciclopirox shampoo for seborrheic dermatitis for the full treatment time even though symptoms may have improved. Notify the physician if there is no improvement after 4 weeks.
  • Inform the physician if the area of application shows signs of increased initation (redness, itching, burning, blistering, swelling, or oozing).

Manufactured by:

Encube Ethicals Pvt. Ltd.

Plot No. C-1, Madkaim

Industrial Estate, Madkaim,

Post: Mardol, Panda,

Goa - 403 404, India.

Distributed by:

Encube Ethicals, Inc.

200 Meredith Drive,

Suite 202, Durham,

NC27713 USA

Revision: 05/2025

PATIENT INFORMATION

SPL PATIENT PACKAGE INSERT SECTION

Ciclopirox (sye" kloe pir' ox) Shampoo

Important: For use on the scalp only. Do not get ciclopirox shampoo in your eyes, mouth, or vagina.

What is ciclopirox shampoo?

Ciclopirox shampoo is a prescription medicine used on the scalp to treat adults with a skin condition called seborrheic dermatitis.

It is not known if ciclopirox shampoo is safe and effective in children under 16 years of age.

What should I tell my doctor before using ciclopirox shampoo?

Before using ciclopirox shampoo, tell your doctor if you:

  • have any other medical conditions
  • are pregnant or plan to become pregnant. It is not known if ciclopirox shampoo will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if ciclopirox shampoo passes into your breast milk.
  • are taking prescription and nonprescription medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How should I use ciclopirox shampoo?

  • Use ciclopirox shampoo exactly as your doctor tells you to use it.
  • Wash your hair using ciclopirox shampoo 2 times each week for 4 weeks. There should be at least 3 days between each time you use ciclopirox shampoo.
  • Use ciclopirox shampoo for 4 weeks even if your skin condition improves.
  • Tell your doctor if your scalp condition is not getting better after you have used ciclopirox shampoo for 4 weeks.
  • Do not swallow ciclopirox shampoo.
  • Avoid getting ciclopirox shampoo in your eyes. If ciclopirox shampoo gets into your eyes, rinse them well with water.

How should I apply ciclopirox shampoo?

  • Wet your hair and apply approximately 1 teaspoon of ciclopirox shampoo to your scalp. You may use up to 2 teaspoons of ciclopirox shampoo if you have long hair. Lather and leave ciclopirox shampoo on your hair and scalp for 3 minutes. You may use a timer.
  • After 3 minutes have passed, rinse your hair and scalp.

What are the possible side effects of ciclopirox shampoo?

The most common side effects of ciclopirox shampoo include: itching, burning, and redness of the scalp. Tell your doctor if you get any of these symptoms and they become worse or do not go away, or if you get blistering, swelling, or oozing in your scalp.

These are not all the possible side effects of ciclopirox shampoo. For more information, ask your doctor.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store ciclopirox shampoo?

  • Store ciclopirox shampoo at room temperature, between 59°F to 86°F (15°Cto30°C).
  • Safely throw away any unused ciclopirox shampoo after you finish your treatment.

Keep ciclopirox shampoo and all medicines out of the reach of children.

General information about ciclopirox shampoo

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ciclopirox shampoo for a condition for which it was not prescribed. Do not give ciclopirox shampoo to other people, even if they have the same symptoms you have. It may harm them.

You can ask your pharmacist or doctor for information about ciclopirox shampoo that is written for health professionals.

For more information about ciclopirox shampoo, call 1-833-285-4151.

What are the ingredients in ciclopirox shampoo?

Active ingredient: ciclopirox

Inactive ingredients: disodium laureth sulfosuccinate, laureth-2, purified water, sodium chloride, and sodium laureth sulfate.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Manufactured by:

Encube Ethicals Pvt. Ltd.

PlotNo. C-1, Madkaim

Industrial Estate, Madkaim,

Post: Mardol, Panda,

Goa - 403 404, India.

Distributed by:

Encube Ethicals, Inc.

200 Meredith Drive,

Suite 202, Durham,

NC 27713 USA

Revision: 05/2025

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 21922-105-52

Ciclopirox Shampoo 1%

For Topical Use Only

Not for Ophthalmic,

Oral or Intravaginal Use.

Keep Out of Reach of Children

RX only

120 mL

carton
carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
250344ciclopirox 1 % Medicated ShampooPSN1
250344ciclopirox 10 MG/ML Medicated ShampooSCD1
250344ciclopirox 1 % Medicated ShampooSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CICLOPIROX Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d24c6245-86b5-4444-bc75-c1ac73ab3016Product name120180612
c7015f08-288e-4cfa-93b5-f4959a4814aeProduct name120150324
3f974526-143f-9d19-ee0c-98eeee0cdc3fProduct name120140508
5c035cac-559a-7171-c5cb-f0bd0d0fbc86Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
21922-105-52CICLOPIROX120 mL in 1 BOTTLESHAMPOO1201
21922-105-52CICLOPIROX1 in 1 CARTONSHAMPOO11

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
21922-105-52ML - Milliliter21922-105cefdefee-75da-47cf-8132-1e86a16eea1812026-03-17

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
21922-10521922-105-52

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A209975-001CICLOPIROXCICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A209975-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05c2088c7a36db…
2026-09-14 22:38:342026-08A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-0584e616aacf4f…
2026-08-18 06:07:402026-07A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-0531067a03dcf5…
2025-08-23 18:47 UTC2025-08A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-056a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-0503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-052680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-055bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-0579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-051e350fbaab3a…
2024-05-31 18:47 UTC2024-05A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-058072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-055c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-055d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-054b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-0574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-0587673890dc5c…
2021-03-12 10:30 UTC2021-03A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-055aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-058869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-053f01610625f2…
2019-09-15 20:21 UTC2019-09A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05b00525d2431f…
2019-07-19 19:46 UTC2019-07A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-056a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-051c564ffb4f44…
2023-12-20 04:57 UTC2023-12A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-059b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-05a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A209975-001CICLOPIROX1%SHAMPOO / TOPICAL2018-04-053f0d92c62455…
2023-05-13 08:27 UTC2023-05A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-05053a50430f4f…
2023-01-26 05:58 UTC2023-01A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-053bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A209975-001CICLOPIROX1%SHAMPOO / TOPICALAT2018-04-053a93d1ddd44b…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09A209975-001AT1c2088c7a36db…
2026-09-14 22:38:342026-08A209975-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A209975-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A209975-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A209975-001AT131067a03dcf5…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A209975-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A209975-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A209975-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A209975-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A209975-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A209975-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A209975-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A209975-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A209975-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209975-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209975-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A209975-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A209975-001AT1ea99ee380514…
2023-05-13 08:27 UTC2023-05A209975-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A209975-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A209975-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A209975-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A209975-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A209975-001AT1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A209975-001AT1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CICLOPIROXCICLOPIROXEncube Ethicals, Inc.cb456f2e-6645-4cc4-8e71-299c47ccb6b72026-01-30Warnings, Adverse reactionsExact identifier
ndc (package): 21922-105-52
ndc (product): 21922-105
ndc11 (package): 21922010552
spl id: 1b7b23aa-fc6d-4b37-b5db-7fd7bc994bf3
spl set id: cb456f2e-6645-4cc4-8e71-299c47ccb6b7

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.